• Molecular NameLosartan
  • SynonymDUP 89; Losartan Potassium
  • Weight422.92
  • Drugbank_IDDB00678
  • ACS_NO114798-26-4
  • Show 2D model
  • LogP (experiment)4.01
  • LogP (predicted, AB/LogP v2.0)3.51
  • pkaN/A
  • LogD (pH=7, predicted)0.68
  • Solubility (experiment)N/A
  • LogS (predicted, ACD/Labs)(ph=7)-3.39
  • LogSw (predicted, AB/LogsW2.0)0.07
  • Sw (mg/ml) (predicted, ACD/Labs)0.01
  • No.of HBond Donors2
  • No.of HBond Acceptors7
  • No.of Rotatable Bonds8
  • TPSA92.51
  • StatusFDA approved
  • AdministrationN/A
  • PharmacologyAn angiotensin II receptor antagonist drug used mainly to treat high blood pressure (hypertension).
  • Absorption_value80.0
  • Absorption (description)Losartan is readily absorbed after oral administration.
  • Caco_2N/A
  • Bioavailability34.0
  • Protein binding98.7
  • Volume of distribution (VD)0.45 L/kg
  • Blood/Plasma Partitioning ratio (D_blood)N/A
  • MetabollsmHepatic (CYP2C9, CYP3A4). The drug undergoes extensive first-pass metabolism to form the active 5-carboxylic acid metabolite, E-3174, as well as a number of inactive metabolites. After administration, peak plasma concentrations of losartan and E-3174 occur at about 1 h and 3 to 4 h, respectively.
  • Half life2.5 h
  • ExcretionIt is excreted in urine (35%) and in faeces (60%) via bile as the unchanged drug and as its metabolites. There is no evidence for accumulation of the drug.
  • Urinary Excretion12
  • Clerance8.1 ml/min/kg
  • ToxicityGenerally well tolerated but fetal toxicity has been observed.
  • LD50 (rat)LD50=1000 mg/kg
  • LD50 (mouse)N/A